All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The HIV Nef protein is a multifunctional virulence factor that perturbs intracellular membranes and signalling and is secreted into exosomes. While Nef-containing exosomes have a distinct proteomic profile, no comprehensive analysis of their miRNA cargo has been carried out. Since Nef functions as a viral suppressor of RNA interference and disturbs the distribution of RNA-induced silencing complex proteins between cells and exosomes, we hypothesized that it might also affect the export of miRNAs into exosomes.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-C172Z | Human anti-Nef(2F) T cell receptor (T36-5), pCDTCR1 | HIV-1 | T36-5 | Human | RFPLTFGWCF | HLA-A24 | Lentiviral | |
TCR-L328 | Human anti-nef T cell receptor (HIV-B8-FL8-2), pCDTCR1 | HIV-l | HIV-B8-FL8-2 | Human | FLKEKGGL | HLA-B8 | Lentiviral | |
TCR-L333 | Human anti-nef T cell receptor (HIV-B60-KL9), pCDTCR1 | HIV-l | HIV-B60-KL9 | Human | KEKGGLEGL | HLA-B60 | Lentiviral | |
TCR-L335 | Human anti-nef T cell receptor (HIV-A3-QK10), pCDTCR1 | HIV-l | HIV-A3-QK10 | Human | QVPLRPMTYK | HLA-A3/A11 | Lentiviral | |
TCR-L336 | Human anti-nef T cell receptor (HIV-A3-QK10-2), pCDTCR1 | HIV-l | HIV-A3-QK10-2 | Human | QVPLRPMTYK | HLA-A3/A11 | Lentiviral | |
TCR-L337 | Human anti-nef T cell receptor (HIV-A3-QK10-3), pCDTCR1 | HIV-l | HIV-A3-QK10-3 | Human | QVPLRPMTYK | HLA-A3/A11 | Lentiviral | |
TCR-L338 | Human anti-nef T cell receptor (HIV-A3-QK10-4), pCDTCR1 | HIV-l | HIV-A3-QK10-4 | Human | QVPLRPMTYK | HLA-A3/A11 | Lentiviral | |
TCR-L339 | Human anti-nef T cell receptor (HIV-A3-QK10-5), pCDTCR1 | HIV-l | HIV-A3-QK10-5 | Human | QVPLRPMTYK | HLA-A3/A11 | Lentiviral | |
TCR-L340 | Human anti-nef T cell receptor (HIV-A3-QK10-6), pCDTCR1 | HIV-l | HIV-A3-QK10-6 | Human | QVPLRPMTYK | HLA-A3 | Lentiviral | |
TCR-L341 | Human anti-nef T cell receptor (HIV-A3-QK10-7), pCDTCR1 | HIV-l | HIV-A3-QK10-7 | Human | QVPLRPMTYK | HLA-A3 | Lentiviral | |
TCR-C458 | Human anti-Nef T cell receptor (CB-C198), pCDTCR1 | HIV-1 | CB-C198 | Human | RYPLTFGWCF | HLA-A*24:02 | Lentiviral vector | |
TCR-C459 | Human anti-Nef T cell receptor (CB-C199), pCDTCR1 | HIV-1 | CB-C199 | Human | RYPLTFGWCF | HLA-A*24:02 | Lentiviral vector | |
TCR-C460 | Human anti-Nef T cell receptor (CB-C200), pCDTCR1 | HIV-1 | CB-C200 | Human | RYPLTFGWCF | HLA-A*24:02 | Lentiviral vector | |
TCR-C461 | Human anti-Nef T cell receptor (CB-C201), pCDTCR1 | HIV-1 | CB-C201 | Human | RYPLTFGWCF | HLA-A*24:02 | Lentiviral vector | |
TCR-C462 | Human anti-Nef T cell receptor (CB-C202), pCDTCR1 | HIV-1 | CB-C202 | Human | RYPLTFGWCF | HLA-A*24:02 | Lentiviral vector | |
TCR-C463 | Human anti-Nef T cell receptor (CB-C203), pCDTCR1 | HIV-1 | CB-C203 | Human | RYPLTFGWCF | HLA-A*24:02 | Lentiviral vector | |
TCR-C464 | Human anti-Nef T cell receptor (CB-C204), pCDTCR1 | HIV-1 | CB-C204 | Human | RYPLTFGWCF | HLA-A*24:02 | Lentiviral vector | |
TCR-C465 | Human anti-Nef T cell receptor (CB-C205), pCDTCR1 | HIV-1 | CB-C205 | Human | RYPLTFGWCF | HLA-A*24:02 | Lentiviral vector | |
TCR-C466 | Human anti-Nef T cell receptor (CB-C206), pCDTCR1 | HIV-1 | CB-C206 | Human | RYPLTFGWCF | HLA-A*24:02 | Lentiviral vector | |
TCR-C467 | Human anti-Nef T cell receptor (CB-C207), pCDTCR1 | HIV-1 | CB-C207 | Human | RYPLTFGWCF | HLA-A*24:02 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION